Bremer Trust National Association acquired a new position in Chemed Co. (NYSE:CHE) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 90 shares of the company’s stock, valued at approximately $25,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Hawaiian Bank boosted its holdings in shares of Chemed by 21.3% in the 4th quarter. First Hawaiian Bank now owns 290 shares of the company’s stock worth $82,000 after purchasing an additional 51 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Chemed by 17.8% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 132,303 shares of the company’s stock worth $42,281,000 after purchasing an additional 19,963 shares in the last quarter. Ontario Teachers Pension Plan Board purchased a new position in shares of Chemed in the 3rd quarter worth about $351,000. Fisher Asset Management LLC boosted its holdings in shares of Chemed by 0.4% in the 4th quarter. Fisher Asset Management LLC now owns 477,261 shares of the company’s stock worth $135,198,000 after purchasing an additional 1,961 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Chemed by 3.4% in the 3rd quarter. Legal & General Group Plc now owns 19,664 shares of the company’s stock worth $6,284,000 after purchasing an additional 641 shares in the last quarter. Hedge funds and other institutional investors own 87.51% of the company’s stock.
In other news, insider Nicholas Michael Westfall sold 5,709 shares of the business’s stock in a transaction dated Tuesday, December 11th. The stock was sold at an average price of $301.75, for a total value of $1,722,690.75. Following the completion of the sale, the insider now owns 16,052 shares of the company’s stock, valued at approximately $4,843,691. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Kevin J. Mcnamara sold 5,000 shares of the business’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $323.47, for a total value of $1,617,350.00. Following the completion of the sale, the chief executive officer now directly owns 155,094 shares of the company’s stock, valued at approximately $50,168,256.18. The disclosure for this sale can be found here. In the last three months, insiders sold 18,173 shares of company stock valued at $5,781,664. 4.82% of the stock is currently owned by corporate insiders.
CHE opened at $325.34 on Thursday. Chemed Co. has a 12-month low of $260.03 and a 12-month high of $335.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.83 and a quick ratio of 1.11. The stock has a market capitalization of $5.20 billion, a PE ratio of 27.27, a PEG ratio of 1.85 and a beta of 1.20.
Chemed (NYSE:CHE) last released its earnings results on Wednesday, February 20th. The company reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.08. Chemed had a return on equity of 36.06% and a net margin of 11.53%. The company had revenue of $457.51 million during the quarter, compared to analyst estimates of $460.50 million. During the same quarter in the previous year, the company posted $2.32 EPS. Chemed’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, equities research analysts expect that Chemed Co. will post 12.77 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 22nd. Stockholders of record on Monday, March 4th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.37%. The ex-dividend date of this dividend is Friday, March 1st. Chemed’s dividend payout ratio (DPR) is presently 10.06%.
CHE has been the subject of a number of research reports. Zacks Investment Research reiterated a “buy” rating and issued a $342.00 price objective on shares of Chemed in a report on Monday, November 12th. Royal Bank of Canada upped their price objective on Chemed from $313.00 to $318.00 and gave the stock a “sector perform” rating in a report on Monday, February 25th.
ILLEGAL ACTIVITY NOTICE: “Bremer Trust National Association Invests $25,000 in Chemed Co. (CHE) Stock” was originally published by Zolmax and is the sole property of of Zolmax. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://zolmax.com/investing/bremer-trust-national-association-invests-25000-in-chemed-co-che-stock/2944341.html.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Story: What is the QQQ ETF?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.